Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 3;9(12):e015933.
doi: 10.1136/bmjgh-2024-015933.

The priority review voucher: a misconceived quid pro quo

Piero Olliaro  1 , Els Torreele  2
Affiliations

The priority review voucher: a misconceived quid pro quo

Piero Olliaro et al. BMJ Glob Health. .
No abstract available

Keywords: Global Health; Public Health.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Suleman F, Low M, Moon S, et al. New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines. BMJ. 2020;368:l4408. doi: 10.1136/bmj.l4408. - DOI - PubMed
    1. Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff (Millwood) 2006;25:313–24. doi: 10.1377/hlthaff.25.2.313. - DOI - PubMed
    1. U. S. Government Accountability Office Drug development: fda’s priority review voucher programs. 2020. https://www.gao.gov/products/gao-20-251 Available.
    1. Ridley DB, Lasanta AM, Storer Jones F, et al. European priority review vouchers for neglected disease product development. BMJ Glob Health. 2024;9:e013686. doi: 10.1136/bmjgh-2023-013686. - DOI - PMC - PubMed
    1. Aerts C, Barrenho E, Miraldo M, et al. The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases. Pharm Med. 2022;36:189–97. doi: 10.1007/s40290-022-00427-x. - DOI - PMC - PubMed

LinkOut - more resources